lonafarnib has been researched along with Experimental Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Groffen, J; Heisterkamp, N; Mishra, S; Zhang, B | 1 |
| Bishop, WR; Choe, K; Daley, GQ; Gerlach, MJ; Hoover, RR; Kirschmeier, P; Koh, EY; Peters, DG; Zhang, H | 1 |
2 other study(ies) available for lonafarnib and Experimental Leukemia
| Article | Year |
|---|---|
A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.
Topics: Administration, Oral; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzamides; Disease Models, Animal; Farnesyltranstransferase; Female; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Experimental; Lymphoma; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Nude; Mice, Transgenic; Piperazines; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Survival Rate; Tumor Cells, Cultured | 2004 |
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Cycle; Cell Division; Enzyme Inhibitors; Farnesyltranstransferase; Genes, abl; Hematopoietic Stem Cells; Humans; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperidines; Pyridines; Spleen; Survival Rate; Transformation, Genetic; Tumor Cells, Cultured | 2001 |